Status:
COMPLETED
Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease
Lead Sponsor:
Chinese University of Hong Kong
Conditions:
Anemia of Chronic Kidney Disease
Eligibility:
All Genders
18+ years
Brief Summary
An observational study to evaluate the effect of erythropoiesis-stimulating agents in treating anaemia of renal disease among adult patients receive palliative care instead of dialysis.
Detailed Description
Erythropoiesis-stimulating agent (ESA) has been commonly used to manage patients with end-stage renal disease receiving dialysis. The effects of ESA, however, are unclear. This study compares the resu...
Eligibility Criteria
Inclusion
- patients aged 18 years and older, who opted for ESA treatment during palliative renal care for \> 360 days between January 1, 2014 and December 31, 2016
Exclusion
- patients who had dialysis or kidney transplant treatment
Key Trial Info
Start Date :
March 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2018
Estimated Enrollment :
78 Patients enrolled
Trial Details
Trial ID
NCT03427801
Start Date
March 1 2017
End Date
December 30 2018
Last Update
January 31 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Prince of Wales Hospital, Chinese University of Hong Kong
Shatin, New Territories, Hong Kong, SAR